Analytical Data
-
基因名
MYH3
- Application
-
别名
MYH3；Myosin-3
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11055
-
表达区间
2-100aa
-
氨基酸序列
SSDTEMEVFGIAAPFLRKSEKERIEAQNQPFDAKTYCFVVDSKEEYAKGK IKSSQDGKVTVETEDNRTLVVKPEDVYAMNPPKFDRIEDMAMLTHLNEP
-
分子量
37 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYH3, a member of the myosin heavy chain family, is critically involved in muscle development and function. Mutations in the MYH3 gene have been linked to various congenital myopathies, including nemaline myopathy and congenital fiber type disproportion. These conditions are characterized by abnormal muscle fiber structure and impaired muscle function, often leading to significant morbidity. Research into recombinant MYH3 protein aims to elucidate the mechanistic roles of MYH3 in muscle contraction and disease pathogenesis. By producing MYH3 as a recombinant protein, scientists can study its structural and functional properties in vitro, facilitating a better understanding of the impacts of specific mutations. This research not only enhances our knowledge of MYH3's role in muscle biology but also opens avenues for potential therapeutic strategies targeting myopathies associated with MYH3 dysfunction. Such approaches could lead to the development of novel treatments or gene therapies that address the underlying genetic causes of these debilitating conditions.
